Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$84.46
▼ $5.47 (-6.1%)
Market data updated: 09/26 12:31 AM
Fundamentals updated: 09/25/2026
News analyzed: 09/26/2026
Market Cap
Not available
Day Range
$84.00 - $86.49
52-Week Range
$15.00 - $115.52
Beta
—
Next Earnings
10.11.2026
Support
$80.72
Resistance
$115.52
ORKA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+461.2% (1Y)
Strengths: 3/19 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 22.37
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 6.2% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
38
Quality
No data available
Value
50
Momentum
23
Risk
48
Sentiment
98
Fundamental
46
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Oruka Therapeutics has centered on its strong investor sentiment and strategic developments. The company’s stock surged over 60% in three months, driven by confidence in its lead candidate, ORKA-001, and upcoming clinical milestones. Analysts, like HC Wainwright’s Mitchell S. Kapoor, maintained a "Buy" rating with a $120 price target. Additionally, Oruka announced the appointment of Todd Edwards as Chief Commercial Officer and filed a $1 billion mixed shelf prospectus for potential future financing, signaling growth and expansion plans. Insider sales were also noted.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Oruka Therapeutics, Inc.. News trend score: 98. Reason: 10 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
44
🎯 Conviction (vs. Emotion)
50
Psychology
60
Fundamentals
46
Technical
23
Valuation
50
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
-7%
Market Narrative
54
Fundamental Reality
50
Narrative Gap
+4
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ORKA’s psychology profile suggests a detached yet cautious market stance, with no dominant bias. The euphoria score (20) hints at lingering optimism despite weak momentum, while panic selling (31) reflects subdued volatility and neutral volume—no extreme panic. The narrative gap (-13) implies sentiment may overestimate fundamentals. The key question: *Is the 20.9% above-200MA a buying anchor or a vulnerability?*
Updated: 09/07/2026, 10:42 PM
👥 What the crowd believes
"HC Wainwright & Co. reiterates Oruka Therapeutics with a Buy and maintains $120 price target."
"Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead."
"Oruka Therapeutics appoints Todd Edwards as Chief Commercial Officer, bringing 25 years of commercial leadership experience."
"Oruka Therapeutics files $1 billion mixed shelf offering."
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in methodology verdicts for ORKA reflects deep contrasts in how these investors approach valuation, risk, and market psychology. Benjamin Graham and his Enterprising Investor variant both flag a lack of sufficient balance-sheet or valuation data, leaving no clear quantitative signal—highlighting their reliance on concrete metrics. Meanwhile, Walter Bagehot’s high score suggests a robust liquidity position, aligning with his focus on financial resilience during crises, while Samuel Armstrong Nelson’s mid-range score leans on technical cycle positioning, seeing it as oversold. At the other end, Fisher, Veblen, and Housel dismiss it outright—Fisher for insufficient fundamentals, Veblen for perceived speculative growth chasing, and Housel for volatility that could deter patient long-term holders. Schwager’s disciplined setup contrasts sharply with Livermore’s negative trend verdict, illustrating how similar reward/risk frameworks can clash over directional bias, while Marks’ mixed assessment hints at a business with elevated expectations.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 15%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 97
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 60
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 45
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 39
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 33
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 28
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 25
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 14
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 286 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-22.3%
ROA
-21.6%
ROIC
—
EPS
—
Cash
$46.94M
Total Debt
—
Current Ratio
22.37
Debt/Equity
—
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 29.8.2024 | $19.356 |
| 28.8.2024 | $19.356 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
—
Tangible Book Value per Share (Tangible NAV)
—
Not enough data to compute signals.
Sentiment based on basic keywords (not AI) — 10 positive, 8 neutral, 2 negative out of the last 20 articles.
Yahoo · 24.9.2026
Yahoo · 24.9.2026
Benzinga · 24.9.2026
Benzinga · 24.9.2026
Yahoo · 24.9.2026
Yahoo · 23.9.2026
Yahoo · 23.9.2026
Benzinga · 23.9.2026
Yahoo · 23.9.2026
Yahoo · 23.9.2026
Benzinga · 23.9.2026
Yahoo · 9.9.2026
GlobeNewswire · 9.9.2026
Benzinga · 3.9.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
SeekingAlpha · 27.8.2026
MT Newswires · 24.8.2026
Yahoo · 24.8.2026
GlobeNewswire · 24.8.2026
Oruka Therapeutics, Inc. (ORKA) currently has a StockIQ AI score of 45/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ORKA currently scores 45/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ORKA's technical score is 23/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 22.37; Price is above the 200-day average; Current ratio: 22.37.
Based on the real signals StockIQ computed: ATR: 6.2% of price; Return on equity (ROE): -22.3% (negative); Free cash flow growth: -52.4%.
Yes — ORKA has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 15 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Agarwal Arjun | Open Market Sale | 21.9.2026 | 14,219 | -533 | $95.75 |
| Quinlan Paul T | Exercise of Derivative Securities | 21.9.2026 | 39,995 | +10,000 | $7.80 |
| Quinlan Paul T | Exercise of Derivative Securities | 21.9.2026 | 79,996 | -10,000 | — |
| Quinlan Paul T | Open Market Sale | 21.9.2026 | 33,263 | -3,832 | $93.32 |
| Quinlan Paul T | Open Market Sale | 21.9.2026 | 29,995 | -2,667 | $95.31 |
| Quinlan Paul T | Open Market Sale | 21.9.2026 | 37,095 | -2,900 | $92.37 |
| Quinlan Paul T | Open Market Sale | 21.9.2026 | 32,662 | -601 | $94.44 |
| Goncalves Joana | Open Market Sale | 15.9.2026 | 34,184 | -3,150 | $92.03 |
| Goncalves Joana | Open Market Sale | 15.9.2026 | 32,718 | -100 | $94.22 |
| Quinlan Paul T | Open Market Sale | 15.9.2026 | 29,995 | -1,039 | $95.71 |
| Goncalves Joana | Open Market Sale | 15.9.2026 | 32,818 | -1,366 | $92.99 |
| Goncalves Joana | Exercise of Derivative Securities | 15.9.2026 | 164,992 | -3,500 | — |
| Goncalves Joana | Open Market Sale | 15.9.2026 | 31,771 | -947 | $95.71 |
| Goncalves Joana | Exercise of Derivative Securities | 15.9.2026 | 39,718 | +3,500 | $7.80 |
| Klein Lawrence Otto | Open Market Sale | 15.9.2026 | 923,128 | -2,452 | $95.71 |
| Goncalves Joana | Exercise of Derivative Securities | 15.9.2026 | 36,218 | +3,500 | $6.84 |
| Goncalves Joana | Open Market Sale | 15.9.2026 | 37,334 | -2,384 | $91.10 |
| Sandler Laura Lee | Open Market Sale | 15.9.2026 | 235,478 | -906 | $95.71 |
| Goncalves Joana | Exercise of Derivative Securities | 15.9.2026 | 193,563 | -3,500 | — |
| Agarwal Arjun | Open Market Sale | 15.9.2026 | 14,752 | -560 | $95.71 |
| Agarwal Arjun | Open Market Sale | 11.9.2026 | 17,720 | -4,051 | $92.41 |
| Agarwal Arjun | Exercise of Derivative Securities | 11.9.2026 | 24,771 | +1,459 | $34.39 |
| Agarwal Arjun | Exercise of Derivative Securities | 11.9.2026 | 23,312 | +8,000 | $12.50 |
| Agarwal Arjun | Exercise of Derivative Securities | 11.9.2026 | 58,333 | -1,459 | — |
| Agarwal Arjun | Exercise of Derivative Securities | 11.9.2026 | 84,917 | -8,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,623,327 shares short as of 2026-09-15 · vs. 7,793,678 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.9% of trading volume this week was short selling, vs. 70.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology